Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04846374 · ClinicalTrials.gov registry record
Two is Better Than One: A Novel Venous Access System for Intermittent Apheresis
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 20
- Enrollment target
NCT04846374: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT04846374 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04846374 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Purpose: To describe a novel configuration of venous access for the performance of intermittent apheresis. Participants: 20 participants at UNC who were referred for change from a vortex port to a powerflow port. Procedures (methods): Placement of one of two configurations of the powerflow port and follow up visits between January 1, 2019 and December 31, 2023.
Primary Outcome
The study will compare mean change flow rate for pheresis sessions with the old system versus pheresis sessions with one of two new configurations by averaging the flow rate for up to 5 sessions using the new port configuration.
Interventions
- DEVICE PowerPort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2023-04-14 |
What the finished NCT04846374 record still lists
NCT04846374 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PowerPort is the first listed.
NCT04846374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04846374 about?
NCT04846374 is a clinical study titled "Two is Better Than One: A Novel Venous Access System for Intermittent Apheresis". Purpose: To describe a novel configuration of venous access for the performance of intermittent apheresis. Participants: 20 participants at UNC who were referred for change from a vortex port to a powerflow port. Procedures (methods): Placement of one of two configurations of the powerflow port an...
What is the current status of trial NCT04846374?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-05-26. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04846374?
The interventions under investigation include: PowerPort (DEVICE).
Who is sponsoring clinical trial NCT04846374?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI